Last reviewed · How we verify
TG02
At a glance
| Generic name | TG02 |
|---|---|
| Also known as | No other names., No other names |
| Sponsor | European Organisation for Research and Treatment of Cancer - EORTC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma (PHASE1, PHASE2)
- Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma. (PHASE1)
- Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer (PHASE1)
- Phase I Clinical Study of Oral TG02 Capsule in the Treatment of Recurrent / Progressive High-grade Glioma Patients (PHASE1)
- Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma (PHASE1)
- Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (PHASE1)
- Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TG02 CI brief — competitive landscape report
- TG02 updates RSS · CI watch RSS
- European Organisation for Research and Treatment of Cancer - EORTC portfolio CI